Claims for Patent: 9,278,095

Summary for Patent: 9,278,095

Title:	Bupropion as a modulator of drug activity
Abstract:	This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	14/863,284
Patent Claims:	1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering bupropion with about 40 mg per day to about 500 mg per day of dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein bupropion and dextromethorphan are co-administered once or twice a day, and wherein on the eighth day that bupropion and dextromethorphan are co-administered, the co-administration results in an AUC.sub.0-12 of dextromethorphan that is at least about 20 times the AUC.sub.0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days. 2. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 500 nghr/mL. 3. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is about 800 nghr/mL to about 900 nghr/mL. 4. The method of claim 1, wherein the AUC.sub.0-24 of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 600 nghr/mL. 5. The method of claim 1, wherein the AUC.sub.0-inf of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 1000 nghr/mL. 6. The method of claim 1, wherein the AUC.sub.0-inf of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered is at least about 2000 nghr/mL. 7. The method of claim 1, wherein the C.sub.max of dextromethorphan on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 10 ng/mL. 8. The method of claim 1, wherein the C.sub.max of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 40 ng/mL. 9. The method of claim 1, wherein the C.sub.max of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 60 ng/mL. 10. The method of claim 1, wherein about 40 mg to about 240 mg of dextromethorphan per day is administered to the human being. 11. The method of claim 1, wherein about 40 mg to about 120 mg of dextromethorphan per day is administered to the human being. 12. The method of claim 1, wherein about 60 mg to about 100 mg of dextromethorphan per day is administered to the human being. 13. The method of claim 1, wherein about 200 mg to about 250 mg of bupropion per day is administered to the human being. 14. The method of claim 13, wherein about 60 mg to about 100 mg of dextromethorphan per day is administered to the human being. 15. A method of increasing exposure to dextromethorphan in a human being, comprising co-administering bupropion with about 40 mg per day to about 500 mg per day of dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein bupropion and dextromethorphan are co-administered once or twice a day, and wherein on the eighth day that bupropion and dextromethorphan are co-administered, the co-administration results in an AUC.sub.0-12 of dextromethorphan that is at least about 15 times the AUC.sub.0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days. 16. The method of claim 15, wherein about 40 mg to about 240 mg of dextromethorphan per day is administered to the human being. 17. The method of claim 15, wherein about 40 mg to about 120 mg of dextromethorphan per day is administered to the human being.